Connect with us

Featured

Advanced Micro Devices (AMD)’s FALL IN REVENUE JUST A HITCH

A. Lawrence

Published

on

UXIN tech penny stock price

Advanced Micro Devices, Inc. (NASDAQ: AMD) reported a slump in its revenue in Q2. Management also alerted of the company’s top-line growth to be in mid-single-digit for the year. AMD stock was quick to be sold at the signs of distress amidst other chip stocks. But, this distress is not something that would last long and is just a short-term hitch.

Can AMD Stock Price Come Back Stronger?

The revenue decline was over 13% annually and operating margins have shriveled by 4%. This bust can be credited to the inventory of graphics card channel that stood oversupplied due to the failure of crypto-currency. The company’s expected revenue for Q3 is $1.8 billion at the mid-point of its guidance range. Even though this figure is an increase (9%) as compared to the previous year’s figure, it fails to live up to Wall Street’s expectation of $1.94 billion.

Report] Multi-Billion Dollar Markets Are Ready For A Shake-Up; 1 Biotech Stock Could Hold The Key

The sagging to-line growth is due to the slow demand of the company’s semi-custom chips, as claimed by AMD’s CFO Devinder Kumar. Due to the upcoming launch of next-generation hardware next year by both Sony and Microsoft, the demand for gaming consoles has gone down currently as more and more game enthusiasts are holding off buying the gaming console.

This has largely affected AMD stock price due to the simple reason that the semi-custom chips that the company manufactures are actually used by Sony and Microsoft for their gaming consoles. Due to the fall in current demand, Sony announced a cut in its fiscal 2020’s sale forecast for PlayStation 4, thereby reducing the order of the semi-custom chips. However, with the launch of next-generation gaming hardware, business for AMD is likely to rapidly pace up again.

AMD stock price

Moreover, the company is also making successful strides in its other segments like the Ryzen processors becoming a catalyst for AMD in the CPU space. The launch of AMD’s latest 7-nanometer Ryzen CPUs with their superior performance and lower power consumption would likely gain more market share for the company. Rome, AMD’s new server processor, has also started being shipped and would make its space in the server market. Also, the revenue from AMD’s GPU has also increased in double-digit percentage.

Keeping all these in mind, the slump in Q2’s revenue of the company does seem like a minor bump in the bright road of the company’s future.

Continue Reading
Click to comment

Featured

Alibaba (BABA) Stock Price Signaling Buy Or Sell After The Recent Surge?

Joe Samuel

Published

on

technology stock price

China has grown into the world’s second-largest economy over the past few decades. One Chinese company that mirrors the remarkable growth of the country is Alibaba Group Holding Ltd – ADR (NYSE:BABA). The e-commerce behemoth is rightly called the ‘Amazon of China’ and it has grown at a remarkable pace over the past two decades.

Key Details

However, Jack Ma, who oversaw the company’s rise has decided to depart. Most analysts believe that Alibaba stock is still a buy despite this development. There are several factors to consider, however.

Jack Ma may have departed but the robust business model that he has created is still in place. That will likely continue to help drive the company’s growth. The Alibaba marketplace is massive and it allows Chinese companies to sell abroad, while at the same time allowing domestic consumers to sell to each other.

Sales Continue To Drive Margins

On mobile devices alone, the company recorded as many as 755 million monthly active users in China. On top of e-commerce, Alibaba has also branched into a tech company. It has its own cloud service known as Alibaba Cloud and has also created its own payments platform Alipay. Alipay already boasts of as many as 600 million users.

Moreover, despite trade tensions with the United States, the Chinese economy is expected to grow over the next decade and expand the size of the middle class. China is already the biggest market for e-commerce companies and the expanding middle class will continue to contribute towards its hyper-growth. Joseph Tsai, the company’s vice chairman stated that even smaller cities in China are expanding rapidly and that retail consumption would hit $7 trillion by 2030.

Last but not least, the company has consistently delivered impressive financial results and in the recent quarters, it has managed to beat analysts’ earnings estimates comfortably.

Continue Reading

Featured

Stock Price Newsletter – September 23, 2019

Jon Phillip

Published

on

biotech stock to watch 2019

3 Small-Cap Biotech Stocks To Watch In Coming Weeks

The fact that biotech companies often improve on existing treatments, makes them a far more attractive target for a range of investors. Here is a look at three biotech stocks to watch during the last few weeks of the quarter.

See For Yourself, CLICK HERE


This Stock is Looking to Disrupt the Multi-Billion Dollar Defense Industry

Global spending on security solutions is projected to reach $7.4 billion in 2019 and increase to over $11.3 billion by 2025 with a CAGR of 8.2% and is forecast to see consistent growth for the next several years. What Could This Mean For ONE COMPANY?

Read More


Multi-Billion Dollar Markets Are Ready For A Shake-Up

There’s no denying that biotechnology is one of the hottest markets in the world. Right now a multi-billion-dollar segment is ready for a shakeup and one biotech stock could hold the secret to doing just that!

Continue Reading

Continue Reading

Biotechnology

3 Small-Cap Biotech Stocks To Watch In Coming Weeks

Joe Samuel

Published

on

stock market today

Biotech has been one of the hottest sectors for investors for as long as it has existed and the reasons are self-evident. It is a sector that uses cutting edge technology and comes up with treatments for a wide range of diseases.

Moreover, the fact that biotech companies often improve on existing treatments, makes them a far more attractive target for a range of investors. Here is a look at three biotech stocks to watch during the last few weeks of the quarter.

PharmaCyte Biotech (PMCB)

There has been no lack of attention on biotech penny stocks this year.  At the beginning of August, one small biotech stock broke to highs of over $10 from a starting price below $2 a share after releasing news. PharmaCyte Biotech (PMCB) focuses on ways to effectively deliver treatments to patients with diseases ranging from cancer to diabetes. 

The company’s proprietary cellulose-based live-cell encapsulation technology known as “Cell-in-a-Box®is the platform that the company uses to develop its therapy delivery methods.  For most of the quarter, shares of PMCB stock have traded between $0.033 and $0.04 with volume recently surging.

On September 19, PharmaCyte saw more than 6 million shares trade; well above its daily average. Most of the attention surrounding the company has been on two things. First, its progress with Cell-In-A-Box and the application for Pancreatic cancer has continued to progress. The company brought on Dr. Manuel Hidalgo, has confirmed that he will be Principal Investigator (PI) for PharmaCyte’s planned clinical trial in locally advanced, inoperable pancreatic cancer (LAPC) now that he is at Weill Cornell Medical Center.

What To Watch For

This week PharmaCyte (PMCB) will host a call designed to update all shareholders and the investment community simultaneously of material developments. The call will cover PharmaCyte’s preparations for submission of its Investigational New Drug application (IND) to the U.S. FDA to treat locally advanced, inoperable pancreatic cancer. It will also cover developments related to PharmaCyte’s product pipeline. PharmaCyte has been working on these and will discuss things not yet reported in a press release.

Catalyst Pharmaceuticals (CPRX)

The first one to watch is Catalyst Pharmaceuticals Inc (NASDAQ:CPRX). It is a small-cap stock engaged in developing medicines for rare diseases. Catalyst managed to get an approval for one of its products from the FDA earlier this year.

Since the approval of the Lambert-Eaton myasthenic syndrome (LEMS treating medicine Firdapse, Catalyst stock went on a massive rally from January to April. The approval of a rival drug halted the rally. Only after a civil suit from Catalyst did the stock stabilize somewhat.

Last week, Catalyst stock received a fresh boost after the company announced that it was going to make a secondary offering. However, the company decided to pull the offering the very next day and that affected the stock price once again.

What To Watch For

Analysts believe that pulling the secondary offering was the right long term decisions and this stock could be heading for another rally soon.

Eyepoint Pharmaceuticals (EYPT)

The biotech stock that could prove to be a major winner in the biotech sector this month is that of Eyepoint Pharmaceuticals Inc (NASDAQ:EYPT). There are two factors at play. The company revenues are going to rise significantly in the coming years due to the commercial launch of two medicines.

The first one is Yutiq, which is meant for the treatment of chronic non-infectious uveitis and the other one is Dexycu, which is meant for postoperative ocular inflammation.

What To Watch For

The company is currently trading at only double that of its future revenue and that is a very attractive multiple. EYPT stock has caught the attention of analysts on Wall Street. Guggenheim has set a 12-month target price of $4, which reflects 116% gains during the period.

stock market news today
Disclaimer: Pursuant to an agreement between MIDAM VENTURES, LLC and Complete Investment And Management LLC, a Non-affiliate Third Party, Midam was hired for a period from 07/09/2019 – 8/09/2019 to publicly disseminate information about PharmaCyte Biotech including on the Website and other media including Facebook and Twitter. We were paid $150,000 (CASH) for & were paid “0” shares of restricted common shares. We were paid an additional $150,000 (CASH) BY Complete Investment And Management LLC, a Non-affiliate Third Party, AND HAVE EXTENDED coverage for a period from 8/12/2019 – 9/12/2019. We may buy or sell additional shares of PharmaCyte Biotech in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information. Click Here For Full Disclaimer

Continue Reading

Join Our Newsletter

Get stock alerts, news & trending stock alerts straight to your inbox!


Privacy Policy

We keep all user information pricate & promise to never spam.*

Stock Price Free Text List

Search Stock Price (StockPrice.com)




Trending

Subscribe Now & Begin Receiving Free Stocks News, Articles, Trade Alerts & MORE, all 100% FREE!

We are your #1 source for all things Stock Market & Finance, Subscribe Below!

Privacy Policy: We will NEVER share, sell, barter, etc. any of our subscribers information for any reason ever! By subscribing you agree we can send you via email our free e-newsletter on stock market & finance related, articles, news and trade alerts. Further questions please contact privacy@stockprice.com